Talarozole
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| N-(2-Benzothioazolyl)-N-[4-[2-ethyl-1-(1,2,4-triazo-1-yl)butyl]phenyl]amine | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Routes | oral, topical |
| Identifiers | |
| CAS number | 201410-53-9 |
| ATC code | None |
| PubChem | CID 9799888 |
| UNII | XKD9N5CJ6W  |
| Chemical data | |
| Formula | C21H23N5S |
| Mol. mass | 377.505 g/mol |
| SMILES | eMolecules & PubChem |
 (what is this?) (verify) |
|
Talarozole (formerly R115866, planned trade name Rambazole) is an investigational drug for the treatment of acne, psoriasis and other keratinization disorders.
Talarozole inhibits the metabolism of retinoic acid by blocking the cytochrome P450 enzyme isoform CYP26, a retinoic acid hydroxylase. Because of this mechanism, it is called a retinoic acid metabolism blocking agent (RAMBA).[1]
[edit] References
- ^ Giltaire, S; Herphelin F, Frankart A, Hérin M, Stoppie P, Poumay Y (11 December 2008). "The CYP26 inhibitor R115866 potentiates the effects of all-trans retinoic acid on cultured human epidermal keratinocytes". Br J Dermatol 160 (3): 505–13. doi:10.1111/j.1365-2133.2008.08960.x. PMID 19120344.
 |
This dermatologic drug article is a stub. You can help Wikipedia by expanding it. |
